Your browser doesn't support javascript.
Venous Thromboembolic Disease in COVID-19, Pathophysiology, Therapy and Prophylaxis.
Dybowska, Malgorzata; Wyrostkiewicz, Dorota; Opoka, Lucyna; Lewandowska, Katarzyna; Sobiecka, Malgorzata; Tomkowski, Witold; Szturmowicz, Monika.
  • Dybowska M; Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland.
  • Wyrostkiewicz D; Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland.
  • Opoka L; Department of Radiology, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland.
  • Lewandowska K; Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland.
  • Sobiecka M; Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland.
  • Tomkowski W; Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland.
  • Szturmowicz M; Department of Lung Diseases, National Tuberculosis and Lung Diseases Research Institute, 01-138 Warsaw, Poland.
Int J Mol Sci ; 23(18)2022 Sep 08.
Article in English | MEDLINE | ID: covidwho-2010124
ABSTRACT
For over two years, the world has been facing the epidemiological and health challenge of the coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Growing problems are also complications after the development of COVID-19 in the form of post and long- COVID syndromes, posing a challenge for the medical community, both for clinicians and the scientific world. SARS-CoV-2 infection is associated with an increased risk of cardiovascular complications, especially thromboembolic complications, which are associated with both thrombosis of small and very small vessels due to immunothrombosis, and the development of venous thromboembolism. Low molecular wight heparin (LMHW) are the basic agents used in the prevention and treatment of thromboembolic complications in COVID-19. There is still a great deal of controversy regarding both the prevention and treatment of thromboembolic complications, including the prophylaxis dose or the optimal duration of anticoagulant treatment in patients with an episode of venous thromboembolism.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Venous Thrombosis / Venous Thromboembolism / COVID-19 / COVID-19 Drug Treatment Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Year: 2022 Document Type: Article Affiliation country: Ijms231810372

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Venous Thrombosis / Venous Thromboembolism / COVID-19 / COVID-19 Drug Treatment Type of study: Prognostic study Topics: Long Covid Limits: Humans Language: English Year: 2022 Document Type: Article Affiliation country: Ijms231810372